Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
BLASST-1
BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
- NCT03294304 ↗
- Completed
- Masonic Cancer Center, University of Minnesota
- Standard
We haven't built an HCP commentary report on BLASST-1 (nivolumab, cisplatin and 1 more in Muscle Invasive Bladder Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BLASST-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 13 | |
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- BLASST-1 (Bladder Cancer Signal Seeking Trial): Phase II Trial of Neoadjuvant Nivolumab With Cisplatin and Gemcitabine in Muscle-Invasive Bladder Cancer (MIBC) Patients Undergoing Radical Cystectomy
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- Nivolumab; Cisplatin; Gemcitabine
- Arms
- Nivolumab, Cisplatin, & Gemcitabine · Experimental
- Enrollment
- 43
- Primary outcomes
- Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging to ≤pT1pN0 Which Includes pT0, pT1, pTa and pTis)
- Sponsor
- Masonic Cancer Center, University of Minnesota with Bristol-Myers Squibb
- Start
- Jan 29, 2018
- Primary completion
- Jun 5, 2020
- Results posted
- Yes
- Registry record
- NCT03294304 · updated Dec 16, 2021